Ridinilazole

Drug Profile

Ridinilazole

Alternative Names: SMT-19969

Latest Information Update: 11 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Summit plc
  • Developer Summit Therapeutics
  • Class Antibacterials; Benzimidazoles; Pyridines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Clostridium infections

Most Recent Events

  • 01 Feb 2017 Summit Therapeutics plans two phase III trials for Clostridium infections in the first half of 2018
  • 11 May 2016 Ridinilazole is available for licensing as of 11 May 2016. http://www.summitplc.com/
  • 28 Apr 2016 Summit Therapeutics receives patent allowance for Ridinilazole in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top